infections. These patients are classified as having secondary TTP (2) (3) (4) .
Bone marrow necrosis (BMN) is a relatively uncommon clinicopathologic entity. The etiology is diverse, and malignancy, especially hematopoietic in origin, is the most common underlying disease of BMN. The most common symptoms are bone pain, fever, and fatigue. The most common laboratory findings were variable and associated with underlying disease, but anemia, leukopenia, thrombocytopenia, and high lactate dehydrogenase (LDH) and alkaline phosphatase levels were detected in the majority of the cases and were also seen in other series (5) .
We presented a patient with the rare association of TTP and BMN, displayed as the first manifestations of a lung cancer. As far as we know, this is the first case of TTP and BMN associated with clinically occult lung cancer.
CASE REPORT
A 53-year-old man was admitted to emergency room with complaints of fever, weakness, Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease that is characterized by Moschcowitz's pentad (1): thrombocytopenia, microangiopathic hemolytic anemia (MAHA), fluctuating neurological signs, renal failure, and fever. Its association with malignancy is long well recognized but is infrequent. In this regard, approximately 5% of patients with cancer can develop TTP, being a sign of disseminated disease.
The majority of patients with TTP are adults who suddenly develop clinical signs without any underlying disease; this is referred to as idiopathic TTP. In a significant number of patients, however, TTP is associated with a variety of clinical conditions, including autoimmune disease, stem cell transplantation, malignancy, drug, pregnancy, and and generalized ecchymosis. The fever was accompanied with night sweats, a feeling of weakness for the previous month, and generalized ecchymosis for 3 days. His medical history was unremarkable. On physical examination, pale conjunctivas and generalized ecchymosis, especially on the lower extremities, were observed. His temperature was 37.9°C, and his blood pressure was 100/55 mm Hg. The pulse was 110 beats per minute. Laboratory examination showed the following: hemoglobin, 4.3 g/dL; the white blood cell count, 9500 per mm 3 , and the platelet count, 10 000 per mL. A blood smear showed reticulocytosis, poikilocytosis, and numerous schistocytes. In order to investigate the etiology of pancytopenia, a bone marrow biopsy was planned. It was consistent with ischemic necrosis in the bone marrow ( Fig. 1 ). The erythrocyte sedimentation rate was 90 mm/h, and his glucose level was 118 mg/dL. Biochemical examination showed that total bilirubin was 1.71 mg/dL with 1.17 mg/dL of indirect bilirubin. The total protein level was 5.5 g/dL. The albumin level was 3.3 g/dL. The aspartate aminotransferase level was 246 U/L. The alanine aminotransferase level was 118 U/L. The LDH level was 1814 U/L, and the calcium level was 7.7 mg/dL. Serum creatinine and urea nitrogen were normal. The partial thromboplastin time, the thromboplastin time, and fibrinogen were within normal ranges. The D-dimer test was positive. The direct and indirect Coombs tests were negative. Urine analysis revealed proteinuria (50 mg/dL) and microhematuria.
Because of the presence of thrombocytopenia, MAHA, and fever with an elevated level of LDH, we diagnosed the patient as TTP, and a plasma exchange program was immediately initiated. By that time, we investigated the etiology of bilateral pleural effusion and hilar opacities that was encountered on the chest x-ray; therefore, a thorax computed tomography scan was performed that showed multiple paratracheal, precarinal, and aorticopulmonary lymphadenopathies, bilateral pleural effusion and collapse-consolidation areas, and multiple minimal nodular opacities. Fiberoptic bronchoscopy was performed, and multiple biopsies were taken to investigate the underlying pathology. Pathological examination showed malignant epithelial cells in the bronchial mucosa consistent with non-small cell lung cancer (Fig. 2) .
Two days after admission to the hospital, the patient developed a fluctuating confusional state with no localizing neurological signs. The plasma exchange procedure was applied daily for 10 days. At the same time, chemotherapy was commenced (cisplatin 75 mg/m2 d1 + etoposide 100 mg/m2 d1-d3), which was given as 3 courses. The LDH level was decreased, and the thrombocyte count improved. At 3 months after the chemotherapy, a repeated thorax computed tomography scan showed minimal regression of the previous lesions; however, after the third course of chemotherapy, LDH levels were found to be elevated, and the thrombocyte count was decreased, which suggested a relapse of TTP. The plasma exchange program was reinitiated with the new chemotherapy protocol (carboplatin AUC6 d1 + vinorelbine 30 mg/m 2 d1 and d8). The patient's condition deteriorated, and he died a week later.
DISCUSSION
In 1925, Moschcowitz initially described TTP in a 16-year-old girl who died rapidly with multiple organ failure (6) . He recognized the importance of disseminated microvascular thrombi at autopsy; these thrombi remain the hallmark of pathologic diagnosis. In 1966, Amorosi and Ultmann described 16 patients and reviewed the 255 previously reported patients (7) . Their review established the pentad of clinical features that became diagnostic criteria, and their detailed patient descriptions report the same issues that we struggle with today: the extreme variety of presenting features and clinical course, the predilection for pregnancy, and the diagnostic confusion with other diseases. The current era in our knowledge began with the observation by Moake et al in 1982 of unusually large multimers von Willebrand factor (ULVWF) in the plasma of 4 patients with chronic relapsing TTP (8) . These ULVWF multimers promote plateletdependent microvascular thrombosis, suggesting that patients lacked a von Willebrand factor protease able to reduce the size of von Willebrand factor multimers by cleavage. The von Willebrand factor-cleaving protease is now known as ADAMTS13, but the main finding of these subsequent studies is that only approximately 50% of patients with overt clinical disease have low plasma level of the protease. Moreover, considering that severely deficient ADAMTS13 activity may not always be sufficient to cause TTP, other proteins that might be involved in the mechanism underlying TTP are investigated. ADAMTS13 is a risk factor for the development of TTP, but it is neither always necessary nor sufficient to cause TTP (9). ADAMTS13 was not evaluated because of technical insufficiency in this case.
The majority of patients with TTP are adults who suddenly develop clinical signs without any underlying disease. This is referred to as idiopathic TTP; however, in a significant number of patients, TTP is associated with a variety of clinical conditions, including autoimmune disease, stem cell transplantation, malignancy, drugs, pregnancy, and infection. These patients are classified as having secondary TTP (2) (3) (4) . Classification of 290 Japanese patients with TTP-hemolytic uremic syndrome showed that 108 patients were idiopathic and 105 patients were secondary TTP. Secondary TTP was categorized according to underlying disease as follows: autoimmune disease (n = 43), malignancy (n = 21), stem cell transplantation (n = 19), pregnancy (n = 9), drugs (n = 8), and other causes (n = 5) (10).
We presented a patient with the rare association of TTP and BMN, displayed as the first manifestations of a lung cancer. The association between TTP and BMN has been described in a case by Gonzalez et al (11) in 2002; TTP and BMN were the first manifestation of a metastatic gastric adenocarcinoma. In addition, Lee et al (12) described a patient with association of TTP and BMN as the first manifestation of an advanced colon cancer; however, there is no reported patient in the English literature suggesting an association of TTP and BMN with lung cancer.
The pathophysiology of BMN and TTP is not entirely understood, but both of them seem to be the consequences of endothelial cell injury, systemic in the case of TTP and limited to marrow in BMN. It has been postulated for the latter that the endothelial injury causes vascular obstruction in the bone marrow, being mediated by tumor necrosis factor-α (11) . In paraneoplastic TTP, tumor cell emboli, together with immune complexes, could generate endothelial damage that would finally give rise to intimal proliferation and platelet aggregation and deposition. MAHA is considered to be caused by mechanical fragmentation of red blood cells traversing this injured microvasculature. On the other hand, the diagnosis of TTP continues to be difficult because fever, neurological disturbance, and renal impairment are not consistently found in all patients, at least in the early stages of disease. In addition, the neurological and renal problems are more unusual in cancer-related TTP than in the idiopathic form; however, MAHA and thrombocytopenia hint at the diagnosis of TTP, especially when accompanied by a suspicious clinical picture (11) .
The prognosis of TTP in cancer patients is poor, but early diagnosis of TTP may alter the course of the disease. It is recommended that all cancer patients presenting with unexplained anemia and thrombocytopenia should be evaluated not only for bone marrow metastasis, but also for coexistence with secondary TTP (13) . In conclusion, TTP needs to be searched for an occult neoplasm, especially when associated with BMN. The concomitance of TTP and BMN further worsens the adverse prognosis of these disorders so that a rapid management of the patient is necessary because of the quick progression.
